Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Intravenous Immunoglobulin Expands Regulatory T Cells in Autoimmune Rheumatic Disease

JAGADEESH BAYRY, LUC MOUTHON and SRINI V. KAVERI
The Journal of Rheumatology February 2012, 39 (2) 450-451; DOI: https://doi.org/10.3899/jrheum.111123
JAGADEESH BAYRY
DVM, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jagadeesh.bayry@crc.jussieu.fr
LUC MOUTHON
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SRINI V. KAVERI
DVM, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

This article has a correction. Please see:

  • Errata - January 01, 2015

To the Editor:

Intravenous immunoglobulin (IVIG) therapy can benefit diverse autoimmune and inflammatory diseases through several mutually nonexclusive mechanisms1,2. In vitro and in vivo studies in experimental models have also demonstrated that IVIG can expand CD4+CD25+ regulatory T cells (Treg), the cells that play a critical role in maintaining immune tolerance3,4. Treg maintain immune tolerance by suppressing the activation and function of both innate and adaptive immune cells, while deficiency of Treg is associated with autoimmune and inflammatory conditions5,6. Since IVIG therapy in autoimmune patients is associated with restoration of immune tolerance, we hypothesized that this effect of IVIG is in part through expansion of Treg in these patients, the bona fide immune regulators.

We analyzed Treg in paired blood samples of patients with autoimmune rheumatic disease before and 72 to 96 hours after high-dose IVIG therapy (human normal immunoglobulin; Tegeline, 2 g/kg per month)1. The patients broadly belonged to 2 groups: those with idiopathic inflammatory myopathy (8 patients, age range 22–57 yrs; 3 men) and those with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (3 patients, age range 61–68 yrs; 2 males). Patients’ data are provided in Table 1. Local ethical committee approval was obtained for collecting blood samples, and patients provided informed consent.

View this table:
  • View inline
  • View popup
Table 1.

Summary of data for patients with autoimmune rheumatic disease.

Peripheral blood mononuclear cells were isolated from the blood samples by Ficoll-density gradient, and CD4+CD25high T cells were analyzed by flow cytometry using fluorescence-conjugated monoclonal antibodies (LSR II; BD Biosciences, Le Pont de Claix, France).

We found that 6 patients, including the 3 with ANCA-associated vasculitis, had substantial increases in the percentage of Treg following IVIG therapy (2.2% ± 0.3% before IVIG therapy and 7.9% ± 1.8% post-IVIG therapy); 3 patients with myopathies (Patients 7, 8, and 11) had marginal enhancement in Treg (1.1% ± 0.6% before IVIG therapy and 1.7% ± 0.7% post-IVIG therapy); and in 2 patients with dermatomyositis (Patients 2 and 6) the percentage of Treg did not change (1.95% ± 0.7% before IVIG therapy and 1.97% ± 0.6% post-IVIG therapy; Figure 1). These results indicate that the antiinflammatory effect of IVIG therapy is associated with enhancement of Treg in autoimmune patients and these Treg might help to restore immune tolerance.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Changes in percentage of regulatory T cells in autoimmune patients before and after IVIG therapy. Peripheral blood mononuclear cells were isolated from heparinized blood samples and CD4+CD25high Treg were analyzed by flow cytometry using fluorescence-conjugated monoclonal antibodies. Circles represent patients. *p < 0.05, paired Student t test.

Although several immunosuppressive drugs including steroids can enhance Treg7, IVIG has an added advantage in that this therapy is not an immunosuppressor, but rather an immunomodulator. Hence adverse effects associated with immunosuppressive therapies can be avoided by IVIG therapy. The enhancement of Treg following IVIG therapy might implicate several mutually nonexclusive mechanisms8,9,10. It is known that inflammatory cytokines suppress Treg8 and by neutralizing these inflammatory mediators, IVIG might favor Treg expansion. In addition, IVIG is known to modulate the maturation and function of innate immune cells, and these modulated innate cells may expand Treg. Alternatively, IVIG can reciprocally regulate pathogenic Th17 and Treg10.

Footnotes

  • Supported by Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie and Université Paris Descartes, European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 260338 ALLFUN.

REFERENCES

  1. 1.↵
    1. Bayry J,
    2. Negi VS,
    3. Kaveri SV
    . Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol 2011;7:349–59.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Seite JF,
    2. Shoenfeld Y,
    3. Youinou P,
    4. Hillion S
    . What is the contents of the magic draft IVIG? Autoimmun Rev 2008;7:435–9.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Kessel A,
    2. Ammuri H,
    3. Peri R,
    4. Pavlotzky ER,
    5. Blank M,
    6. Shoenfeld Y,
    7. et al.
    Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 2007;179:5571–5.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Ephrem A,
    2. Chamat S,
    3. Miquel C,
    4. Fisson S,
    5. Mouthon L,
    6. Caligiuri G,
    7. et al.
    Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: A critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008;111:715–22.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Sakaguchi S,
    2. Miyara M,
    3. Costantino CM,
    4. Hafler DA
    . FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010;10:490–500.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Li X,
    2. Qian L,
    3. Wang G,
    4. Zhang H,
    5. Wang X,
    6. Chen K,
    7. et al.
    T regulatory cells are markedly diminished in diseased salivary glands of patients with primary Sjogren’s syndrome. J Rheumatol 2007;34:2438–45.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. de Paz B,
    2. Alperi-Lopez M,
    3. Ballina-Garcia FJ,
    4. Prado C,
    5. Gutierrez C,
    6. Suarez A
    . Cytokines and regulatory T cells in rheumatoid arthritis and their relationship with response to corticosteroids. J Rheumatol 2010;37:2502–10.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Bayry J,
    2. Siberil S,
    3. Triebel F,
    4. Tough DF,
    5. Kaveri SV
    . Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discov Today 2007;12:548–52.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. De Groot AS,
    2. Moise L,
    3. McMurry JA,
    4. Wambre E,
    5. Van Overtvelt L,
    6. Moingeon P,
    7. et al.
    Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”. Blood 2008;112:3303–11.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Maddur MS,
    2. Vani J,
    3. Hegde P,
    4. Lacroix-Desmazes S,
    5. Kaveri SV,
    6. Bayry J
    . Inhibition of differentiation, amplification and function of human Th17 cells by intravenous immunoglobulin. J Allergy Clin Immunol 2011;127:823–30.
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 39, Issue 2
1 Feb 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Intravenous Immunoglobulin Expands Regulatory T Cells in Autoimmune Rheumatic Disease
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Intravenous Immunoglobulin Expands Regulatory T Cells in Autoimmune Rheumatic Disease
JAGADEESH BAYRY, LUC MOUTHON, SRINI V. KAVERI
The Journal of Rheumatology Feb 2012, 39 (2) 450-451; DOI: 10.3899/jrheum.111123

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Intravenous Immunoglobulin Expands Regulatory T Cells in Autoimmune Rheumatic Disease
JAGADEESH BAYRY, LUC MOUTHON, SRINI V. KAVERI
The Journal of Rheumatology Feb 2012, 39 (2) 450-451; DOI: 10.3899/jrheum.111123
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Seasonal Variations and Their Influence on Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Relapse
  • Survival After Lung Transplantation in Patients With Rheumatoid Arthritis-Associated Lung Disease
  • High-Sensitivity Cardiac Troponin T as a Marker to Improve Cardiovascular Disease Risk Assessment Among Patients With Rheumatoid Arthritis
Show more Letters

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire